Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.50M | 1.31M | 1.28M | 963.90K | 583.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50M | 1.31M | 1.28M | 963.90K | 583.30K |
| Cost of Revenue | 9.36M | 9.05M | 8.33M | 7.97M | 7.63M |
| Gross Profit | -7.86M | -7.74M | -7.05M | -7.01M | -7.04M |
| SG&A Expenses | 6.46M | 7.03M | 7.14M | 6.99M | 8.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.82M | 16.08M | 15.47M | 14.96M | 16.06M |
| Operating Income | -14.32M | -14.77M | -14.19M | -14.00M | -15.47M |
| Income Before Tax | -12.96M | -13.51M | -12.93M | -12.72M | -14.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.96 | -13.51 | -12.93 | -12.72 | -14.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.96M | -13.51M | -12.93M | -12.72M | -14.29M |
| EBIT | -14.32M | -14.77M | -14.19M | -14.00M | -15.47M |
| EBITDA | -14.30M | -14.75M | -14.18M | -13.99M | -15.46M |
| EPS Basic | -2.38 | -2.81 | -3.03 | -3.32 | -4.00 |
| Normalized Basic EPS | -1.49 | -1.76 | -1.90 | -2.08 | -2.50 |
| EPS Diluted | -2.38 | -2.81 | -3.03 | -3.32 | -4.00 |
| Normalized Diluted EPS | -1.49 | -1.76 | -1.90 | -2.08 | -2.50 |
| Average Basic Shares Outstanding | 22.03M | 19.81M | 17.61M | 15.40M | 14.46M |
| Average Diluted Shares Outstanding | 22.03M | 19.81M | 17.61M | 15.40M | 14.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |